19 October 2017
The portfolio of materials is designed to reduce packaging falsification and tampering in the pharmaceutical sector.
The need to protect the safety of pharmaceutical products has risen in recent years, and Avery Dennison has developed a portfolio of materials designed to reduce packaging falsification and tampering in the pharmaceutical sector.
“Drug counterfeiting is a major global problem. Patient safety is compromised by product manipulation and substitution, and manufacturers can experience damage to their brand image, sales and revenue,” explains Gabriela Gregor, Avery Dennison’s project manager for pharmaceutical labeling. “Our products can change the game in protecting patient safety and safeguarding manufacturer reputation.”
One key product range in the portfolio is the Tamper-evident Seal Range, which, when combined with newly formulated adhesive S799P, makes tampering with cartons more difficult, and eases compliance with the EU Medicine Directive 2011/62/EU, which is designed to prevent “falsified medicines” from entering the legal prescription supply chain, and also applies to some over-the-counter products.